Scarica l'app Stockscreener
5.12
4.66%
-0.25
Dopo l'orario di chiusura:
5.09
-0.03
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.37
Aprire:
$5.32
Volume 24 ore:
132.39K
Relative Volume:
0.50
Capitalizzazione di mercato:
$50.94M
Reddito:
$20.34M
Utile/perdita netta:
$-24.52M
Rapporto P/E:
-1.4317
EPS:
-3.5761
Flusso di cassa netto:
$-5.92M
1 W Prestazione:
+16.63%
1M Prestazione:
-1.92%
6M Prestazione:
-27.92%
1 anno Prestazione:
-19.63%
Intervallo 1D:
$5.09
$5.51
Intervallo di 1 settimana:
$4.45
$5.51
Portata 52W:
$3.53
$9.12
Scynexis Inc Stock (SCYX) Company Profile
Nome
Scynexis Inc
Settore
Telefono
201-884-5485
Indirizzo
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
5.12 | 43.68M | 20.34M | -24.52M | -5.92M | -3.5761 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-22 | Iniziato | Guggenheim | Buy |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Aggiornamento | Needham | Hold → Buy |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-10 | Iniziato | ROTH Capital | Buy |
| 2017-05-09 | Downgrade | Needham | Buy → Hold |
| 2017-03-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-07 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2016-08-17 | Iniziato | Guggenheim | Buy |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-08-09 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Iniziato | Brean Capital | Buy |
| 2015-12-29 | Iniziato | WBB Securities | Speculative Buy |
| 2015-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-06-10 | Iniziato | Needham | Buy |
| 2014-05-29 | Iniziato | Canaccord Genuity | Buy |
| 2014-05-29 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Scynexis Inc Borsa (SCYX) Ultime notizie
Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247 - AllSci
Scynexis wins BARDA contract worth up to $214 million for antifungal SCY-247 - The Pharma Letter
Which USD 46 million antifungal biotech just won a government contract worth up to USD 214 million? - kalkine.ca
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline - TipRanks
SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Scynexis stock surges on $214M BARDA contract for SCY-247 - Yahoo Finance
SCYX Stock Draws Trader Focus As New CFO And ADPKD Pivot Take Shape - timothysykes.com
SCYX Stock Draws Traders As Leadership And Kidney Pivot Advance - StocksToTrade
SCYNEXIS Wins BARDA Contract Worth Up to $214 Million for SCY-247 - citybiz
SCYNEXIS secures BARDA contract for antifungal development - Investing.com
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract - Yahoo Finance
Why is Scynexis stock surging today? By Investing.com - Investing.com South Africa
A U.S. health agency could provide up to about $214 million to develop an antifungal treatment if all options are exercised. - Stock Titan
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch - TradingView
SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada
SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com
SCYNEXIS Appoints Nephrology Veteran Steven K. Burke to Board of Directors - Minichart
SCYNEXIS adds veteran biopharma leader to board - TipRanks
Scynexis appoints Steven Burke to board of directors - Investing.com
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - The Manila Times
SCYNEXIS (Nasdaq:SCYX)Stock Analysis - Simply Wall Street
SCYNEXIS, Inc. (SCYX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Scynexis appoints Todd Minga as senior VP of R&D By Investing.com - Investing.com Australia
Scynexis appoints Todd Minga as senior VP of R&D - Investing.com
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - The Manila Times
A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com
Scynexis names Sanjay Subramanian as chief financial officer - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Form 8K Scynexis Inc For: 10 September By Investing.com - Investing.com Nigeria
SCYNEXIS, Inc. Announces Executive Changes, Effective September 9, 2026 - marketscreener.com
SCYX Looks 72.0% Undervalued on GF Value™ but Remains a Possible Value Trap - GuruFocus
SCYNEXIS, Inc. Announces CFO Changes, Effective September 9, 2026 - marketscreener.com
SCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipeline - citybiz
SCYNEXIS Names Sanjay Subramanian as CFO - marketscreener.com
Scynexis names Sanjay Subramanian as chief financial officer By Investing.com - Investing.com India
SCYNEXIS appoints new CFO amid leadership transition - TipRanks
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer - The Manila Times
Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer - TradingView
A new finance chief brings 20 years of experience to SCYNEXIS - Stock Titan
Scynexis Appoints New CFO Amid Transition - Intellectia AI
Scynexis Inc (SCYX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SCYNEXIS Inc. (SCYX) Advances 1.92% to $5.32 as Stock Holds Above Key $5.05 SupportDiamond Pattern - vinanet.vn
Scynexis Inc (SCYX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Scynexis Inc Azioni (SCYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):